Fujisawa hopes for drug approval

Fujisawa Pharmaceutical, Japan’s fifth-largest drugmaker, expects Europe to approve its anti-fungal drug in the first half of 2006.

The company will present additional data of clinical tests to the European Agency for the Evaluation of Medicinal Products, the company said in a statement filed to the Tokyo Stock Exchange.

Fujisawa had originally expected to get approval for its micafungin sodium treatment by the end of this year.